Business Description
Cartesian Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US8162121045
Compare
Compare
Traded in other countries / regions
RNAC.USA1S70.Germany Index Membership
Russell 2000Russell 3000Russell 2000 IPO Date
2016-06-22Description
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 12.83 | |||||
| Equity-to-Asset | -0.05 | |||||
| Debt-to-Equity | -0.65 | |||||
| Debt-to-EBITDA | -0.35 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -1.74 | |||||
| Beneish M-Score | -2.77 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -53.5 | |||||
| 3-Year EBITDA Growth Rate | -43.7 | |||||
| 3-Year EPS without NRI Growth Rate | 28.3 | |||||
| 3-Year FCF Growth Rate | 51.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -24.78 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | -81.9 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 60.28 | |||||
| 9-Day RSI | 57.84 | |||||
| 14-Day RSI | 54.93 | |||||
| 3-1 Month Momentum % | -23.46 | |||||
| 6-1 Month Momentum % | -46.62 | |||||
| 12-1 Month Momentum % | -60.61 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 12.34 | |||||
| Quick Ratio | 12.34 | |||||
| Cash Ratio | 12.03 | |||||
| Days Sales Outstanding | 88.68 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -84.2 | |||||
| Shareholder Yield % | 0.78 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -131.27 | |||||
| Net Margin % | -112.11 | |||||
| EBITDA Margin % | -117.28 | |||||
| FCF Margin % | -118.31 | |||||
| ROA % | -9.71 | |||||
| ROIC % | -19 | |||||
| 3-Year ROIIC % | -15.92 | |||||
| ROC (Joel Greenblatt) % | -215.99 | |||||
| ROCE % | -11.4 | |||||
| Years of Profitability over Past 10-Year | 1 | |||||
| Moat score | 3 | |||||
| Tariff score | 7 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 5.95 | |||||
| EV-to-EBIT | -2.8 | |||||
| EV-to-EBITDA | -2.95 | |||||
| EV-to-Revenue | 3.46 | |||||
| EV-to-Forward-Revenue | 69.62 | |||||
| EV-to-FCF | -2.93 | |||||
| Price-to-GF-Value | 2.85 | |||||
| Earnings Yield (Greenblatt) % | -35.71 | |||||
| FCF Yield % | -13.7 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers